HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

Mantle cell lymphoma (MCL) is a highly aggressive and heterogeneous B-cell lymphoma. Though Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown great efficacy as a single agent for MCL treatment, the real-world use of ibrutinib is still subject to limitations. Our previous study has shown t...

Full description

Bibliographic Details
Main Authors:	Ziwen Lu, Zhixin Wang, Zhigang Tu, Hanqing Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Series:	Frontiers in Pharmacology
Subjects:	Hsp90 ganetespib mantle cell lymphoma Btk ibrutinib apoptosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.864194/full

Similar Items

Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice
by: Mahmoud E. Youssef, et al.
Published: (2023-03-01)

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
by: Roberto Gomez-Casal, et al.
Published: (2015-05-01)

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
by: Philipp von Hundelshausen, et al.
Published: (2021-03-01)

An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein
by: Jessica McCready, et al.
Published: (2014-04-01)

Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments
by: Enzo M. Scutigliani, et al.
Published: (2022-10-01)

The Chaperone System in Salivary Glands: Hsp90 Prospects for Differential Diagnosis and Treatment of Malignant Tumors
by: Charbel A. Basset, et al.
Published: (2022-08-01)

Ganetespib (STA-9090) augments sorafenib efficacy via necroptosis induction in hepatocellular carcinoma: Implications from preclinical data for a novel therapeutic approach
by: Sameh Saber, et al.
Published: (2023-08-01)

A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer
by: Deepa S. Subramaniam, et al.
Published: (2018-03-01)

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
by: Tadeusz Robak, et al.
Published: (2022-02-01)

Upregulation of TGF-β-induced HSP27 by HSP90 inhibitors in osteoblasts
by: Gen Kuroyanagi, et al.
Published: (2022-05-01)

Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data
by: Vivek Sulekha Radhakrishnan, et al.
Published: (2022-07-01)

High-Throughput Screen of Natural Product Libraries for Hsp90 Inhibitors
by: Jason Davenport, et al.
Published: (2014-02-01)

The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep
by: Cheng Chang, et al.
Published: (2023-01-01)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
by: Neeraj Jain, et al.
Published: (2023-08-01)

Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
by: Dong R, et al.
Published: (2022-09-01)

Cytosolic Hsp90 Isoform-Specific Functions and Clinical Significance
by: Samarpan Maiti, et al.
Published: (2022-08-01)

Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells
by: Emilie Logie, et al.
Published: (2021-03-01)

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
by: Ana J. Rodrigues Moita, et al.
Published: (2020-11-01)

Role of Heat Shock Proteins (HSP70 and HSP90) in Viral Infection
by: Anna Lubkowska, et al.
Published: (2021-08-01)

Bruton’s Tyrosine Kinase Inhibitors: Recent Updates
by: Amneh Fares, et al.
Published: (2024-02-01)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
by: Young‐Woo Jeon, et al.
Published: (2019-11-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Obada Ababneh, et al.
Published: (2022-05-01)

Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N‐terminal Inhibitors Without Induction of Heat Shock Response
by: Dr. Peng Liu, et al.
Published: (2019-03-01)

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
by: Yuchen Zhang, et al.
Published: (2022-11-01)

Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions
by: Katarzyna Szklener, et al.
Published: (2022-04-01)

Development of machine learning models for the screening of potential HSP90 inhibitors
by: Mohd Imran Khan, et al.
Published: (2022-10-01)

Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton’s Tyrosine Kinase Inhibitor
by: Keun Woo Lee, et al.
Published: (2020-04-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Abdullah Mohammad Khan
Published: (2022-04-01)

HSP90 inhibitor inhibits glycolysis and promotes apoptosis of mouse hepatocarcinoma cell line H22
by: LIU Na-si, CAO Ming-yue, WU You-ming, HUANG Wei, YANG Nan, LIU Yan-yong
Published: (2020-07-01)

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Research in context
by: Urban Novak, et al.
Published: (2023-10-01)

Inhibitors of the <i>Plasmodium falciparum</i> Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future
by: Melissa Louise Stofberg, et al.
Published: (2021-10-01)

May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical Experience in a Patient with Chronic Lymphocytic Leukemia
by: Javier Molina-Cerrillo, et al.
Published: (2021-01-01)

Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis
by: Issei Nakade, et al.
Published: (2023-11-01)

The HSP90 Inhibitor, AUY-922, Ameliorates the Development of Nitrogen Mustard-Induced Pulmonary Fibrosis and Lung Dysfunction in Mice
by: Pavel Solopov, et al.
Published: (2020-07-01)

The Chaperone System in Tumors of the Vocal Cords: Quantity and Distribution Changes of Hsp10, Hsp27, Hsp60, and Hsp90 during Carcinogenesis
by: Alessandro Pitruzzella, et al.
Published: (2024-01-01)

Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma
by: Ángela Marrugal, et al.
Published: (2021-03-01)

The Role of HSP90 Inhibitors in the Treatment of Cardiovascular Diseases
by: Shiyu Qi, et al.
Published: (2022-10-01)

Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice
by: Huanan Rao, et al.
Published: (2022-11-01)

Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity
by: Hyewon Cho, et al.
Published: (2020-10-01)

Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway
by: Ye Zhang, et al.
Published: (2021-12-01)